CODEN [USA]: IAJPBB ISSN: 2349-7750

INDO AMERICAN JOURNAL OF
PHARMACEUTICAL SCIENCES

http://doi.org/10.5281/zenodo.1495135

Available online at: http://www.iajps.com *Research Article*

A STUDY ON PATIENTS WITH LONG-LASTING MYELOID LEUKEMIA POSSESSING REORGANIZATION OF BCR-ABL DIVERSITY

Dr. Rabiya Farrukh, Dr. Muhammad Masroor Sadiq, Dr. Ahsan Malik
Sheikh Zayed Medical College and Hospital Rahim Yar Khan

Abstract:
Objective: *Ph or rearrangement genetic material (Chromosome), BCR-ABL within Long-lasting Chronic Myeloid Leukemia (CML) is originated as of a shared translocation of chromosome among ABL gene on BCR gene on chromosome 22 and chromosome 9. There are many dimensions in This chimeric protein and therefore diverse medical actions. The diversity of BCR-ABL reorganization in patients is determined in this research study along with Ph^+CML in Pakistan.*
Methods: *The study was carried out at Sheikh Zayed Hospital Rahim Yar Khan. Blood specimens of 25 patients with CML were obtained to detect numerous BCR-ABL transcripts through performing RT-PCR.*
Results: *All samples displayed BCR-ABL reorganizations. In the patients 95% showed p210 BCR-ABL reorganizations i.e. 32% (n=8) were having b2a2 and 59% (n=15) were possessing b3a2 reorganizations. Similar appearance as of b3a2 /b2a2 reorganization and p190 (e1a3) reorganization was also recognized in three patients.*
Conclusion: *The study showed that the patients were possessing p210 BCR-ABL reorganizations. The occurrence of similar appearance and infrequent combination transcriptions were lower.*
Keywords: *Hereditary Malfunction, Symbolized, Translocation of Chromosome, Monocytosis, Thrombocythemia, Transilluminator.*

Corresponding author:
Dr. Rabiya Farrukh,
Sheikh Zayed Medical College and Hospital,
Rahim Yar Khan

QR code

Please cite this article in press Rabiya Farrukh et al., **A Study on Patients with Long-Lasting Myeloid Leukemia Possessing Reorganization of BCR-ABL Diversity.,** *Indo Am. J. P. Sci, 2018; 05(11).*

INTRODUCTION:

The contribution of CML found to 20% of all leukaemias identified in elder persons. It is considered the first human distortion attached with a single acquired hereditary malfunction. The pathognomonic indicator related to CML is Ph chromosome resultant from mutual translocation of chromosome amongst the extended arms of chromosomes nine and twenty-two. The gene ABL is fused on the chromosome nine along with the gene BCR on the chromosome twenty-two making an oncogene named as BCR-ALB [1]. Every fusion protein possesses the persistent size of ABL protein but having different lengths of BCR protein [2]. ABL is having eleven exons and is expressed as "a". Different joints of initial exon fallouts in two isoforms in which one is 1 and another is 1b [3]. The dividing line in the ABL gene is among exon 'a2' and 1b or 1a [4]. BCR is having twenty-three exons and is expressed as "e". Breakdowns in the gene BCR happens in the single region from 03 types i.e. Micro, Minor, and Major symbolized as μBCR, mBCR and M BCR. M-BCR outspreads as of exon 12 to exon 16. The dividing line within M-BCR connects exon 2 of ABL with exon 13 or 14. Resultantly, fusion transcriptions happen e13a2 and e14a2 are translated into protein 210kDa (p210BCR-ABL) respectively. In more than 95% of cases, P210BCR-ABL is detected among ph+ CML and a single case out of three cases with Ph+ ALL [5]. m-BCR indulges with intron one and connects exon one (el) along with a2 that results into a shorter transcript of fusion, e1a2. It encrypts protein 190kDa (p190BCR-ABL) as observed mainly in ph+ ALL furthermore, in very few cases of CML. In this type of CML, the Monocytosis is mainly obvious and there are lower values of the appearance of these p 190 type transcript in comparison with p120 which shows, there is a resemblance in the results of substitute primary mRNA splicing [6]. μ-BCR contains intron 19 and provides an outcome within the shape by joining a2 related to ABL along with exon 19 related to BCR resulting into e19a2. This encrypts 230kDa protein (p230BCR-ABL). The present unique synthesis is observed within N-CML often in Acute Myeloid (AML) and ph+ CML [4, 6]. Tyrosine kinase action is shown in initiated form through all BCR -ABL fusion proteins. P210 [BCR -ABL] has lower action as compared to P190 [BCR-ABL] which results in higher potential to bring an awful alteration [1]. Random cases within further bonds like b2a3, e6a2, b3a3, e2a2, or e1a3 are stated along with CML and ALL in patients. [4].

METHODS:

The research was carried out at Sheikh Zayed Hospital Rahim Yar Khan. We applied the method including detected CML patients and the patients cured by Hydroxyurea. BCR-ABL or existence of Ph chromosome reorganizations. Patients must be at the age of eighteen or above. Male and female both genders were eligible for participation. We excluded the patients which were having BCR-ABL Negative CML History related to Myeloproliferative sickness (MPD) like PV necessary thrombocythemia (ET) moreover, IMF, and the patients cured through tyrosine kinase inhibitor. Within the earlier mentioned duration, the CML patients after covering prerequisites were enabled to get participate in our research study and the total strength of participants was 25. An informed consent was obtained from the participants and all necessary approvals regarding ethics were obtained from the Ethical committee of BMU. Case report forms were used for saving bio-data information of the patients comprising bone marrow biopsy reports, CBC, gender and age. Entire blood samples were taken in EDTA (Ethylene Diamine Tetra Acetic Acid) hoses. The RNA removed from plasma was utilized for recognizing the breakpoints in BCR-ABL and Sleeplex kit methodology was accordingly used in performing RT-PCR. Test bands among positive control were pictured by the usage of gel transilluminator. The dimensions of PCR were proved by comparing to a DNA ladder and the Gel translated in accordance with BCR-ABL indicator (M) by usage of user manual of Sleeplex Leukemia detection was taken as reference. M was utilized to enhance estimated dimensions related to the target product directed on an electrophoresis of gel. A combination was there related to BCR-ABL (e1a2, b2a2) in BCR-ABL positive control. The kit possessed both of the PC and the M. Data analysis was made through SPSS and calculation of repetition was explained statistically.

RESULTS:

The average age of the participants was (50 ± 3) years. Patients CBC indicated the enhanced leukocyte count along with the entire left shift. Findings related to bone marrow were in accordance with the CML. The whole number of samples was positive for BCR-ABL reorganizations. Majority of the patients comprising over 95 % indicated p210 BCR-ABL reorganizations. In 95% cases 60% cases indicated b3a2 and 33% cases indicted b2a2 reorganizations. Cases found for co-expression of b3a2/b2a2 reorganizations were 4%. It was found that 1 case (4%) of p190 BCR-ABL was included.

Table – I: Cycling situations of RT-PCR in BCR-ABL

Segment	Cycle Count	Temp (C)	Time Duration (Minutes)
Initial duration	1	940	15
Denaturation	37	940	0.5
Annealing	37	600	1.5
Extension	37	720	1.5
Final extension	1	720	10







Table – II: Repetition of expression of BCR-ABL dividing line in CML

BCR - ABL Breakpoints	Number	Percentage
b3a2	14	56.00
b2a2	2	8.00
b3a2/b2a2	1	4.00
e1a3	1	4.00
e1a2	1	4.00



DISCUSSION:

Various sorts of BCR-ABL reorganizations are linked along with many types of medical progression and diagnosis. The CML occurrence and its different BCR-ABL transcripts repetition show difference amongst diverse ethnic circumstances [7]. Many molecular methods such as Southern blot, FISH and Conventional RT-PCR are now being used for identification of BCR-ABL gene. But, Conventional RT-PRC in absence of cytogenetics can fail to detect unique cases without using correct primers. Conventional RT-PCR includes two and more pair of primer, otherwise, it is alike Multiplex RT-PCR. Recently, it is used as a reliable technique for identification of atypical and typical BCR-ABL transcript within a reaction process [5]. In this study Multiplex, RT-PCR was utilized for assessing the BCR-ABL reorganizations amongst the CML patients. Primers which were utilized in our study identified BCR-ABL reorganizations with eight types within one PCR reaction. It was observed that there is a possibility to detect typical BCR-ABL fusion transcripts like b3a2 and b2a2 furthermore, atypical sorts missing ABL exon a2 like b3a3 and b2a3. Assessment for e1a3 and e1a2 was also made within transcriptions subsequent from BCR dividing line outside M-BCR. It was obvious that 92% patients were having fusion genes linking with the M-BCR area in compliance with the protein p210. In this 60% patients were having b3a2 and 32% were having b2a2 reorganizations. So, the number of patients with b3a2 was two times higher as compared to the patients with b2a2. The discoveries in our study among BCR-ABL reorganizations are alike findings of another study stated by Iqbal et al [8]. Statistics reported by them were related to Pakistan populace with Ph+CML indicated the repetition of b2a2 and b3a2 to be 33% and 63% correspondingly. The Same reports have also been represented before now. It was found by Reiter et al that the occurrence of b2a2 and b3a2 reorganizations within the CML patients 31.30% and 68.40% correspondingly [9]. Yaghmaie et al. presented that within Iranian populace b2a2 and b3a2 were 20% and 63% respectively [4]. Goh et al. represented that b2a2 and b3a2 were 32% and 67% respectively in Korean populace [5]. Ito et al. represented that repetition of b2a2 and b3a2 were 30.50% and 67.20% respectively in Japanese populace [11]. In Thailand populace, Udomsakdi et al represented that b2a2 and b3a2 were 31% and 61% respectively [12]. As like other studies represented, maximum of the patients expressed p210 BCR-ABL reorganizations in our study. Expression of b2a2 and b3a2 reorganizations was harmonious with the Mexican, Korean, Thai and Japanese Populace. No cases of p190/p210 BCR-ABL transcript of co-expression was found and the expression of p230 was also missing. Only a single case (04%) was indicating two and more types of mRNA i.e. b2a3/b2a2 transcription. The reason behind co-expression may be a result of a phenotypic difference or alternative splicing. It could also be because of the presence of many cells' lines of Leukemia with many of BCR-ANL transcript indication [13]. It is found with rare occurrence but Yaghmaie et al. and Goh et al. have reported the co-expression of two and more transcript [4, 5, 13]. In our study, a single rare case of p210 transcript e1a3 was detected. Roman et al. detected the first case, Goh et al. detected the second case by utilizing Multiplex RT-PCR and it was reported third time in our case for the e1a3 transcript within a patient participant with Ph+ CML [5, 14]. It is suggested by the reports that p190 [BCR-ABL] CML is linked along with a lower result to the therapy Tyrosine Kinase inhibitor [15]. Comparatively, a smaller number of studies is present concerning the importance of BCR-ABL transcript type. Type of transcript can have clinical importance as per the suggestion of few reports. They can be helpful within the pathobiology of t (9; 22)- positive Leukemic cells. CML patient with b3a2 transcripts was having greater platelet count as compared to b2a2 as reported by Perego et al. [16]. Prejzner et al presented that the patients with b3a2 transcripts were having greater endurance as compared to b2a2 [17]. So, a comprehensive survey among the Pakistan Populace within the CML patients must be managed and the patients should be surveyed to study every fusion transcript prognosis.

CONCLUSION:

The study showed that the patients were possessing p210 BCR-ABL reorganizations. The occurrence of similar appearance and infrequent combination transcriptions were lower.

REFERENCES:

1. Goh HG, Hwang JY, Kim SH, Lee YH, Kim YL, Kim DW. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR Translational Res. 2006; 148:249–256.
2. Kim YL, Hwang JY, Kim CC, Kim DW. Analysis of BCR-ABL fusion transcripts of CML patients in Korea. Korean J Hematol. 2001;36(4):292-298.
3. Iqbal Z, Manzoor F, Iqbal M, Ali S, Sheikh N, Khan M, et al. Frequency of Bcr-Abl fusion oncogene splice variants associated with Chronic Myeloid Leukemia. J Cancer Therapy.2011;2:176-180. doi: 10.4236/jct.2011.22022

4. Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL Fusion Transcripts in Iranian Patients with Chronic Myeloid Leukemia. Arch Iranian Med. 2008;11(3):247–251. doi: 08113/AIM.003.
5. Kantarjian HM, Talpaz M, Giles F, Brein SO, Cortes J. New insights into the pathophysiology of CML and Imatinib resistance. Ann Intern Med.2006;45(12):913-923.
6. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukaemia. Blood.2000;96(10):3343-3353.
7. Zhao X, Ghaffari S, Lodish H, Malesh VN, Kim PS. Structure of BCR-ABL oncoprotein oligomerization domain. Nature. 2002; 9:117-120
8. Pluck H, Dorey K, Superti-Furga G. Autoinhibition of c-Abl. Cell. 2002;108(2):247-259.
9. Reiter E, Greinix HT, Brugger S, Keil F, Rabitsch W, Mannhalter C, et al. Long-term follow-up after allogeneic stem cell transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 1998;22(Supp14): S86–S88.
10. Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O'Brien S, Rios MB, et al. The Breakpoint Cluster Region Site in Patients with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. Clinical, Laboratory, and Prognostic Correlations. Cancer. 1995;76(6):992-997.
11. Ito T, Tanaka H, Tanaka K, Ito K, Kyo T, Dohy H, et al. Insertion of a genomic fragment of chromosome 19 between BCR intron 19 and ABL intron 1a in a chronic myeloid leukaemia patient with BCR-ABL (e19a2) transcript. Br J Haematol. 2004; 126:750–755.
12. Udomsakdi-Auewarakul C, U-Pratya Y, Boonmoh S, Vatanavicharn S. Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukaemia by reverse-transcriptase polymerase chain reaction (RT-PCR). J Med Assoc Thai. 2000;83(8):928–935.
13. Henegariu O, Heerema NA, Dlouhy SR, Vance GH, Vogt PH. Multiplex PCR: critical parameters and step-by-step protocol. Biotechniques. 1997; 23:504–511.
14. Roman J, Jimenez A, Barrios M, Castillejo JA, Maldonado J, Torres A. E1A3 as a unique, naturally occurring BCR-ABL transcript in an indolent case of chronic myeloid leukaemia. Br J Haematol. 2001; 114:635-637.
15. Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, et al. Chronic Myeloid Leukemia with P190 BCR-ABL: analysis of characteristics, outcomes and prognostic significance Blood. 2009;114(11):2232-2235.
16. Perego RA, Costantini M, Cornacchini G, Gargantini L, Bianchi C, Pungolino E, et al. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Eur J Cancer. 2000;36(11):1395– 1401.
17. Prejzner W. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes, and survival in patients with chronic myeloid leukaemia. Med Monit. 2002;8: BR191–BR197.